Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Track IMRX with free AI briefings, catalyst countdowns, and dilution alerts.

IMRX · Immuneering Corporation

Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.

$166.1M Cash on Hand
29.9mo Cash Runway
29.7% Short Interest
$17 Analyst Target (6)
Follow IMRX by email Get an email when IMRX reports key news in an SEC filing, pushes back a promised milestone, files for a stock offering, lands on the Downside Radar or has an FDA decision. Free, no account needed.

We send one confirmation email first. Only emails about IMRX, unsubscribe in one click. Privacy

📣 What IMRX Says Is Next

Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.

📄 Latest SEC Filings in Plain English

Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.

🧪 Trial & FDA Catalysts

📊 Drug Pipeline

DrugIndicationMost advanced trialStatus
Atebimetinib Pancreatic Cancer Phase 3 · NCT07562152 Recruiting
GnP Pancreatic Cancer Phase 3 · NCT07562152 Recruiting
mGnP Pancreatic Cancer Phase 3 · NCT07562152 Recruiting
MEK Inhibitor IMM-6-415 Advanced Solid Tumor (Phase 1) Phase 1/2 · NCT06208124 Completed

Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it

💰 Cash Runway & Dilution Risk

IMRX holds $166.1M in cash and short-term investments (as of Sep 30, 2026) and burns about $16.6M/quarter from operations, an estimated runway of 29.9 months at that rate (BioRadar estimate, not company guidance).

Dilution pressure: 15 · Low

Recent financing filings on SEC EDGAR:

Source: SEC EDGAR (XBRL cash flow and financing filings). Dilution Watch: every company ranked → · Get an alert when IMRX files for a raise →

👥 Who Owns IMRX

Insiders 19.9% Institutions 80.1% Public and other holders 0%
HolderTypeShares% of sharesAs of
FMR, LLC Institution (13F) 9,193,275 35.44% 2026-09-30
BlackRock, Inc. Institution (13G, 5%+) 4,356,235 16.79% 2026-06-30
Benjamin J. Zeskind
PRESIDENT AND CEO, Director · +688,000 options
Insider 3,210,179 12.38% 2026-06-23
Sanofi Institution (13F) 2,708,559 10.44% 2026-09-30
Vanguard Capital Management LLC Institution (13F) 2,284,882 8.81% 2026-09-30
Geode Capital Management, LLC Institution (13F) 1,374,279 5.30% 2026-09-30
Price (T.Rowe) Associates Inc Institution (13F) 1,235,304 4.76% 2026-09-30
Peter Feinberg
Director · +41,238 options
Insider 1,161,064 4.48% 2026-01-12
State Street Corporation Institution (13F) 1,152,239 4.44% 2026-09-30
Nuveen, LLC Institution (13F) 869,390 3.35% 2026-09-30
DCF Advisers, LLC Institution (13F) 862,500 3.33% 2026-09-30
Aberdeen Group plc Institution (13F) 784,951 3.03% 2026-09-30

Share count 25,938,064 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the largest 13F holders (13F quarter ending 2026-09-30). Sources have different dates, so the split is approximate. Source: SEC EDGAR.

📈 Recent Insider Activity (Form 4)

Trade dateInsiderTransactionSharesPriceOwned after
2026-11-13
filed 2026-11-16
Gengos Andrew
Purchase (P) 25,000 $3.58 250,000
2026-11-09
filed 2026-11-09
Bogle Grant C.
Option award (A) 66,700 – –
2026-07-16
filed 2026-07-17
Gengos Andrew
Option award (A) 650,000 – –
2026-06-23
filed 2026-06-24
Zeskind Benjamin J.
Purchase (P) 2,400 $4.56 2,315,252
2026-06-15
filed 2026-06-16
Hall Brett Matthew
Purchase (P) 6,035 $4.15 382,531

Only open-market purchases (P) and sales (S) are trading decisions. Awards (A), option exercises (M) and tax withholding (F) are compensation mechanics. Source: SEC Form 4.

Get the full IMRX picture

The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for IMRX and every other ticker you follow. Card required, cancel anytime.

Start 7-day free trial →

Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.